Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHP71R)

• Drug Name: IQ-DAA Drug Info
• Synonyms: Anti-anthrax toxin mAb, IQ; Human monoclonal antibodies (anthrax), IQ; IQN-protective antigen (human mAb), IQ corporation; MAb-based immunotherapy (anthrax), IQ; IQNLF + IQNPA (human mAbs, Bacillus anthracis infection), IQ Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Bacillus anthracis infection	1G40	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMHP71R

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial Protective antigen (Bact pagA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Raxibacumab	DM7QG0M	Anthrax	1B97	Approved	[3]
Valortim	DMYAIUB	Bacterial infection	1A00-1C4Z	Phase 1	[4]
AVP-21D9	DMMWEH6	Bacillus anthracis infection	1G40	Phase 1	[5]
Anthrax vaccine	DM9GSWY	Bacillus anthracis infection	1G40	Discontinued in Phase 1	[6]

Drug(s) Targeting Bacterial Lethal factor (Bact lef)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[7]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[8]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[9]
NSC-622445	DME35CB	Discovery agent	N.A.	Investigative	[10]
N-(Sulfanylacetyl)Tyrosylprolylmethioninamide	DMWJDYZ	Discovery agent	N.A.	Investigative	[7]
N-(3,4-dihydroxybenzyl)oleamide	DM67XSW	Discovery agent	N.A.	Investigative	[11]
N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea	DMT4USP	Discovery agent	N.A.	Investigative	[7]
N-hydroxy-4-(oleamidomethyl)benzamide	DMUSHZK	Discovery agent	N.A.	Investigative	[11]
N-(3,4,5-trihydroxyphenethyl)oleamide	DMQ5USA	Discovery agent	N.A.	Investigative	[12]
N-oleoyl-dopamine	DM1AVCZ	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Lethal factor (Bact lef)	TTIQSC1	LEF_BACAN	Modulator	[2]
Bacterial Protective antigen (Bact pagA)	TT3YGCD	PAG_BACAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020942)
• [2] Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43.
• [3] Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43.
• [4] Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers. Clin Vaccine Immunol. 2011 December; 18(12): 2136-2142.
• [5] Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrob Agents Chemother. 2014 July; 58(7): 3618-3625.
• [6] Annual Reports in Medicinal Chemistry. Annette M. Doherty. 2005. Page(214).
• [7] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [8] Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother. 2007 Jul;51(7):2403-11.
• [9] The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8.
• [10] Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem. 2006 Aug 24;49(17):5232-44.
• [11] Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2467-70.
• [12] Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8.